Back to Authors

Carrigan, Patricia E.

Mayo Clinic

Mayo Clinic in Arizona

Citations 8

Characterization of Farnesyl Diphosphate Farnesyl Transferase 1 ( FDFT1 ) Expression In Cancer
Tüzmen, Şükrü , Watanabe, Aprill, Ekmekçi, Cumhur Gökhan , Carrigan, Patricia E., Shechter, Ishaiahu, Kallioniemi, Olli , Mousses, Spyro, Miller, Laurence J. , Hostetter, Galen H.

Personalized Medicine | November 23, 2018 | Volume: 16 | Issue: 1 | Pages: 51-65

10.2217/pme-2016-0058 Get It

Early Phase Bronchoconstriction in the Mouse Requires Allergen-Specific IgG
Crosby, Jeffrey R., Cieslewicz, Grzegorz, Borchers, Michael T. , Hines, Edie M., Carrigan, Patricia E., Lee, James J. , Lee, Nancy A.

The Journal of Immunology | April 22, 2014 | Volume: 168 | Issue: 8 | Pages: 4050-4054

10.4049/jimmunol.168.8.4050 Get It

Abstract Allergen provocation of allergic asthma patients is often characterized by an initial period of bronchoconstriction, or early phase reaction (EPR), that leads to maximal airway narrowing within 15–30 min, followed by a recovery period returning airway function to baseline within 1–2 h. In this study, we used a defined OVA provocation model and mice deficient for specific leukocyte populations to investigate the cellular/molecular origins of the EPR. OVA-sensitized/challenged wild-type (C57BL/6J) mice displayed an EPR following OVA provocation. However, this response was absent in gene knockout animals deficient of either B or T cells. Moreover, transfer of OVA-specific IgG, but not IgE, before the OVA provocation, was capable of inducing the EPR in both strains of lymphocyte-deficient mice. Interestingly, an EPR was also observed in sensitized/challenged mast cell-deficient mice following an OVA provocation. These data show that the EPR in the mouse is an immunologically based pathophysiological response that requires allergen-specific IgG but occurs independent of mast cell activities. Thus, in the mouse the initial period of bronchoconstriction following allergen exposure may involve neither mast cells nor IgE-mediated events.
Extent and Diversity of Human Alternative Splicing Established by Complementary Database Annotation and Microarray Analysis
Bingham, Jonathan, Carrigan, Patricia E., Srinivasan, Subha , Miller, Laurence J.

OMICS: A Journal of Integrative Biology | February 11, 2008 | Volume: 12 | Issue: 1 | Pages: 83-92

10.1089/omi.2007.0041 Get It

ABSTRACT Alternative splicing generates functional diversity in higher organisms through alternative first and last exons, skipped and included exons, intron retentions and alternative donor, and acceptor sites. In large-scale microarray studies in humans and the mouse, emphasis so far has been placed on exon-skip events, leaving the prevalence and importance of other splice types largely unexplored. Using a new human splice variant database and a genome-wide microarray to probes thousands of splice events of each type, we measured differential expression of splice types across six pair of diverse cell lines and validated the database annotation process. Results suggest that splicing in humans is more complex than simple exon-skip events, which account for a minority of splicing differences. The relative frequency of differential expression of the splice types correlates with what is found by our annotation efforts. In conclusion, alternative splicing in human cells is considerably more complex than the canonical example of the exon skip. The complementary approaches of genome-wide annotation of alternative splicing in human and design of genome-wide splicing microarrays to measure differential splicing in biological samples provide a powerful high-throughput tool to study the role of alternative splicing in human biology.
Distinctive Heavy Metal Composition of Pancreatic Juice in Patients with Pancreatic Carcinoma
Carrigan, Patricia E., Hentz, Joseph G. , Gordon, Gwyneth W. , Morgan, Jennifer L. L. , Raimondo, Massimo , Anbar, Ariel D. , Miller, Laurence J.

Cancer Epidemiology, Biomarkers & Prevention | December 17, 2007 | Volume: 16 | Issue: 12 | Pages: 2656-2663

10.1158/1055-9965.epi-07-0332 Get It

Abstract Epidemiologic studies have shown the health risks of exposure to cigarette smoke and air pollution, with heavy metal composition implicated as contributing to both. Environmental exposure to cigarette smoke has been epidemiologically associated with pancreatic cancer, but the pathophysiologic basis for this is not yet clear. In the current work, we have used inductively coupled plasma mass spectrometry to quantify the metal composition of pancreatic juice collected in response to secretin stimulation in successive patients evaluated for abdominal pain (35 with pancreatic cancer, 30 with chronic pancreatitis, and 35 with normal pancreas). Indeed, metal composition of pancreatic juice was distinctive in patients with pancreatic cancer relative to those without such a cancer. The metal concentrations that were found to have the strongest association with pancreatic cancer were chromium, selenium, and molybdenum, with 1 SD increases in the concentrations of each associated with substantial increases in the odds of having pancreatic cancer relative to those in patients with normal pancreas (210%, 160%, and 76%, respectively). Of note, elevations in concentrations of chromium and selenium did not correlate in individuals, whereas those having a 1 SD increase in the sum of the concentrations of these two metals in their pancreatic juice had a 480% increase in the odds of having pancreatic cancer. Elevations of nickel and zinc correlated with elevated chromium in individuals, with each of these metals known to be present in cigarette smoke, whereas other recognized metal components of cigarette smoke were not elevated. An understanding of why these metals are elevated in pancreatic juice and what effects they might have on pancreatic cells may have important implications for the diagnosis, treatment, and even prevention of pancreatic cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2656–63)
Serine-Arginine Protein Kinase 1 Overexpression Is Associated with Tumorigenic Imbalance in Mitogen-Activated Protein Kinase Pathways in Breast, Colonic, and Pancreatic Carcinomas
Hayes, Gregory M., Carrigan, Patricia E., Miller, Laurence J.

Cancer Research | March 2, 2007 | Volume: 67 | Issue: 5 | Pages: 2072-2080

10.1158/0008-5472.can-06-2969 Get It

Abstract Aberrant patterns of pre-mRNA processing are typical of human malignancies, yet the mechanisms responsible for these changes remain undefined. We have recently shown overexpression of a core splice regulatory protein, serine-arginine protein kinase 1 (SRPK1), in dysplastic and neoplastic pancreatic ductular cells. In the present study, we have established that SRPK1 levels are similarly up-regulated in breast and colonic tumors where its expression increases coordinately with tumor grade. Targeting SRPK1 for inhibition using small interfering RNA in breast and colonic tumor cell lines in vitro resulted in both increased apoptotic potential and enhanced cell killing after treatment with gemcitabine and cisplatin. Recent reports have described multifaceted interactions between the mitogen-activated protein kinase (MAPK) and AKT signaling networks and the splice regulatory machinery. Consequently, we have shown that targeted inhibition of SRPK1 in tumor cells results in reduced phosphorylation of MAPK3, MAPK1, and AKT. Alterations in the splice pattern and resulting expression of MAPK kinase are implicated in mediating the antitumoral effects resulting from SRPK1 down-regulation. The up-regulation of SRPK1 in multiple cancers and its ability to regulate multiple relevant signaling pathways provide support for developing agents to inhibit this kinase for possible broad application to treat epithelial cancers. [Cancer Res 2007;67(5):2072–80]
Targeting the RNA Splicing Machinery as a Novel Treatment Strategy for Pancreatic Carcinoma
Hayes, Gregory M., Carrigan, Patricia E., Beck, Alison M., Miller, Laurence J.

Cancer Research | April 3, 2006 | Volume: 66 | Issue: 7 | Pages: 3819-3827

10.1158/0008-5472.can-05-4065 Get It

Abstract Aberrant patterns of pre-mRNA splicing have been established for many human malignancies, yet the mechanisms responsible for these tumor-specific changes remain undefined and represent a promising area for therapeutic intervention. Using immunohistochemistry, we have localized the expression of a central splicing regulator, serine-arginine protein kinase 1 (SRPK1), to the ductular epithelial cells within human pancreas and have further shown its increased expression in tumors of the pancreas, breast, and colon. Small interfering RNA–mediated down-regulation of SRPK1 in pancreatic tumor cell lines resulted in a dose-dependent decrease in proliferative capacity and increase in apoptotic potential. Coordinately, the disruption of SRPK1 expression resulted in enhanced sensitivity of tumor cells to killing by gemcitabine and/or cisplatin. A dose-dependent reduction in the phosphorylation status of specific SR proteins was detected following the down-regulation of SRPK1 and is likely responsible for the observed alterations in expression of proteins associated with apoptosis and multidrug resistance. These data support SRPK1 as a new, potential target for the treatment of pancreatic ductular cancer that at present remains largely unresponsive to conventional therapies. Furthermore, these results support the development of innovative therapies that target not only specific splice variants arising during tumorigenesis but also the splice regulatory machinery that itself may be abnormal in malignant cells. (Cancer Res 2006; 66(7): 3819-27)
The Heat Shock Protein 70 Cochaperone Hip Enhances Functional Maturation of Glucocorticoid Receptor
Nelson, Gregory M. , Prapapanich, Viravan, Carrigan, Patricia E., Roberts, Patricia J., Smith, David F. , Riggs, Daniel L.

Molecular Endocrinology | April 13, 2004 | Volume: 18 | Issue: 7 | Pages: 1620-1630

10.1210/me.2004-0054 Get It

Interleukin-5 Expression in the Lung Epithelium of Transgenic Mice Leads to Pulmonary Changes Pathognomonic of Asthma
Lee, James J. , McGarry, Michael P. , Farmer, Steven C., Denzler, Karen L., Larson, Kirsten A., Carrigan, Patricia E., Brenneise, Ina E., Horton, Margaret A., Haczku, Angela , Gelfand, Erwin W. , Leikauf, George D. , Lee, Nancy A.

The Journal of Experimental Medicine | July 26, 2002 | Volume: 185 | Issue: 12 | Pages: 2143-2156

10.1084/jem.185.12.2143 Get It

We have generated transgenic mice that constitutively express murine interleukin (IL)-5 in the lung epithelium. Airway expression of this cytokine resulted in a dramatic accumulation of peribronchial eosinophils and striking pathologic changes including the expansion of bronchusassociated lymphoid tissue (BALT), goblet cell hyperplasia, epithelial hypertrophy, and focal collagen deposition. These changes were also accompanied by eosinophil infiltration of the airway lumen. In addition, transgenic animals displayed airway hyperresponsiveness to methacholine in the absence of aerosolized antigen challenge. These findings demonstrate that lung-specific IL-5 expression can induce pathologic changes characteristic of asthma and may provide useful models to evaluate the efficacy of potential respiratory disease therapies or pharmaceuticals.